The Journal of Thoracic Oncology (JTO) for 2013 has increased its impact factor from 4.47 in 2012 to 5.8. This makes JTO the 26th oncology journal and 5th in respiratory journals out of 202 and 53 journals respectively.
Increased overall survival for advanced stage NSCLC patients is associated with availability of less toxic chemotherapy.
DENVER – A 10-year population-based study shows that increased availability of better systemic chemo- and targeted-therapies for patients with advanced non-small cell lung cancer (NSCLC) coincides with increased usage of these therapies. This in turn leads to a significant increase in overall survival.
ROS1 gene fusions are found in 2.4% of Asian patients with lung adenocarcinoma and are associated with young age at diagnosis.
DENVER – ROS1 fusion genes were successfully detected independent of gender or smoking history in young East Asian patients with lung adenocarcinoma, a histological subgroup in non-small cell lung cancer (NSCLC), using multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC) diagnostic tests.
DENVER – La Asociación Internacional para el Estudio de Cáncer de Pulmón (IASLC en Ingles) se complace en anunciar que han sido enviados un número record de abstractos científicos para la 6th Conferencia Latinoamericana de Cáncer de Pulmón (LALCA en Ingles). Con 151 abstractos registrados parece que LALCA 2014 se va a convertir en una gran conferencia científica y educadora.
DENVER – The International Association for the Study of Lung Cancer (IASLC) is pleased to announce that there have been a record number of scientific abstracts for the 6th Latin American Conference on Lung Cancer (LALCA). With 151 submissions, this looks to be a great conference for science and education in Latin America.
DENVER - Investigators of the COSMOS (Continuous Observation of SMOking Subjects) study show good compliance and patient survival outcomes using a 5-year low-dose computed tomography (LDCT) screening protocol in individuals at high-risk of developing lung cancer. This protocol had fewer patients requiring further diagnostic follow-up compared to other studies, including the National Lung Cancer Screening Trial (NLST), with a minimal number of incorrect diagnoses.